Form 4: Apeiron Schedules Conversion to Boost ATAI Life Sciences Stake

Apeiron Investment Group and Christian Angermayer filed a Form 4 detailing a planned conversion of convertible notes into 2.37 million common shares of ATAI Life Sciences N.V. on September 30, 2025.

Summary

• Apeiron Investment Group Ltd. and Christian Angermayer, both 10% owners and directors of ATAI Life Sciences N.V. (ATAI), reported a planned transaction under a Rule 10b5-1(c) plan.
• On September 30, 2025, Apeiron Investment Group Ltd. will convert 147,950 convertible notes into 2,367,200 common shares of ATAI Life Sciences N.V.
• The conversion price for the convertible notes is EUR 17.00 per note.
• These convertible notes were originally acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.
• Following this planned transaction, Apeiron Investment Group Ltd. will beneficially own 53,412,414 common shares indirectly.
• Apeiron Presight Capital Fund II, L.P. will continue to beneficially own 1,799,302 common shares indirectly.
• The derivative securities (convertible notes) will be reduced to 0 following the conversion.

Sentiment

Score: 7

Explanation: The planned conversion of convertible notes into common shares by a significant insider (10% owner and director) is generally viewed as a positive signal, indicating confidence in the company's long-term prospects and a commitment to its equity.

Positives

• The planned conversion of convertible notes into common shares by a significant insider (10% owner and director) demonstrates continued confidence in ATAI Life Sciences N.V.'s future prospects.
• The transaction converts debt-like instruments into equity, potentially strengthening the company's balance sheet by reducing future interest obligations related to these notes.

Future Outlook

This filing details a planned future transaction scheduled for September 30, 2025, indicating a pre-determined strategy for the conversion of existing convertible notes into common equity.

Industry Context

NA

Related Party Transactions

• The convertible notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG, a related entity, with substantially similar terms and economics. Apeiron Investment Group Ltd. is a 10% owner and director of ATAI Life Sciences N.V., indicating a related party relationship.

Stakeholder Impact

• Shareholders: Increased insider ownership may be perceived positively, signaling management and major investor confidence. The conversion of notes into equity could lead to minor dilution if not already accounted for in outstanding share counts, but it also reduces potential future debt obligations.
• Creditors: The conversion of convertible notes into equity reduces the company's outstanding debt-like obligations, potentially improving its credit profile.

Key Dates

Recommendation

The filing indicates a planned future conversion of convertible notes into common shares by a significant insider, which is a positive signal of confidence. However, a Form 4 alone does not provide sufficient comprehensive financial or operational data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this insider action as a supportive data point within a broader investment analysis.

Keywords

ATAI Life Sciences, Apeiron Investment Group, Christian Angermayer, Insider Transaction, Form 4, Beneficial Ownership, Convertible Notes, Equity Conversion, Biotechnology, Pharmaceuticals